Literature DB >> 17004305

Production of biopharmaceuticals and vaccines in plants via the chloroplast genome.

Henry Daniell1.   

Abstract

Transgenic plants offer many advantages, including low cost of production (by elimination of fermenters), storage and transportation; heat stability; and absence of human pathogens. When therapeutic proteins are orally delivered, plant cells protect antigens in the stomach through bioencapsulation and eliminate the need for expensive purification and sterile injections, in addition to development of both systemic and mucosal immunity. Chloroplast genetic engineering offers several advantages, including high levels of transgene expression, transgene containment via maternal inheritance and multi-gene expression in a single transformation event. Hyper-expression of vaccine antigens against cholera, tetanus, anthrax, plague or canine parvovirus (4-31% of total soluble protein, tsp) in transgenic chloroplasts (leaves) or non-green plastids (carrots, tomato), as well as the availability of antibiotic-free selectable markers or the ability to excise selectable marker genes, facilitate oral delivery. Hyper-expression of several therapeutic proteins, including human serum albumin (11.1% tsp), somatotropin (7% tsp), interferon-gamma (6% tsp), anti-microbial peptide (21.5% tsp), facilitates efficient and economic purification. Also, the presence of chaperones and enzymes in chloroplasts facilitate assembly of complex multi-subunit proteins and correct folding of human blood proteins with proper disulfide bonds. Functionality of chloroplast-derived vaccine antigens and therapeutic proteins has been demonstrated by several assays, including the macrophage lysis assay, GM1-ganglioside binding assay, protection of HeLa cells or human lung carcinoma cells against encephalomyocarditis virus, systemic immune response, protection against pathogen challenge, and growth or inhibition of cell cultures. Thus, transgenic chloroplasts are ideal bioreactors for production of functional human and animal therapeutic proteins in an environmentally friendly manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004305     DOI: 10.1002/biot.200600145

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  51 in total

1.  The microalga Chlamydomonas reinhardtii as a platform for the production of human protein therapeutics.

Authors:  Beth A Rasala; Stephen P Mayfield
Journal:  Bioeng Bugs       Date:  2011 Jan-Feb

2.  Transformation of Solanum tuberosum plastids allows high expression levels of β-glucuronidase both in leaves and microtubers developed in vitro.

Authors:  María Eugenia Segretin; Ezequiel Matías Lentz; Sonia Alejandra Wirth; Mauro Miguel Morgenfeld; Fernando Félix Bravo-Almonacid
Journal:  Planta       Date:  2011-11-10       Impact factor: 4.116

Review 3.  From miracle fruit to transgenic tomato: mass production of the taste-modifying protein miraculin in transgenic plants.

Authors:  Kyoko Hiwasa-Tanase; Tadayoshi Hirai; Kazuhisa Kato; Narendra Duhita; Hiroshi Ezura
Journal:  Plant Cell Rep       Date:  2011-12-08       Impact factor: 4.570

Review 4.  Chloroplast vector systems for biotechnology applications.

Authors:  Dheeraj Verma; Henry Daniell
Journal:  Plant Physiol       Date:  2007-12       Impact factor: 8.340

5.  Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce.

Authors:  Huafang Lai; Junyun He; Michael Engle; Michael S Diamond; Qiang Chen
Journal:  Plant Biotechnol J       Date:  2011-08-26       Impact factor: 9.803

6.  Plastid transformation in eggplant (Solanum melongena L.).

Authors:  A K Singh; S S Verma; K C Bansal
Journal:  Transgenic Res       Date:  2009-06-28       Impact factor: 2.788

7.  Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.

Authors:  Syed Waqas Hassan; Mohammad Tahir Waheed; Martin Müller; Jihong Liu Clarke; Zabta Khan Shinwari; Andreas Günter Lössl
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

8.  Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.

Authors:  Abdoreza Davoodi-Semiromi; Melissa Schreiber; Samson Nalapalli; Dheeraj Verma; Nameirakpam D Singh; Robert K Banks; Debopam Chakrabarti; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2009-12-28       Impact factor: 9.803

9.  Towards the development of an oral vaccine against porcine cysticercosis: expression of the protective HP6/TSOL18 antigen in transgenic carrots cells.

Authors:  Elizabeth Monreal-Escalante; Dania O Govea-Alonso; Marisela Hernández; Jacquelynne Cervantes; Jorge A Salazar-González; Andrea Romero-Maldonado; Gabriela Rosas; Teresa Garate; Gladis Fragoso; Edda Sciutto; Sergio Rosales-Mendoza
Journal:  Planta       Date:  2015-11-27       Impact factor: 4.116

Review 10.  Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study.

Authors:  Carla Marusic; Alessandro Vitale; Emanuela Pedrazzini; Marcello Donini; Lorenzo Frigerio; Ralph Bock; Philip J Dix; Matthew S McCabe; Michele Bellucci; Eugenio Benvenuto
Journal:  Transgenic Res       Date:  2009-01-25       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.